News | July 18, 2014

VISION Trial Evaluates First Imaging Atherectomy Catheter to Treat Peripheral Artery Disease

Avinger enrolls first PAD patient in VISION global clinical trial

July 18, 2014 — Avinger announced that John Pigott, M.D., of Jobst Vascular Institute, Toledo, Ohio, enrolled the first patient in the VISION trial, a global investigational device exemption (IDE) clinical trial approved by the U.S. Food and Drug Administration (FDA) to evaluate the Pantheris catheter for the treatment of peripheral artery disease (PAD).

The Pantheris system combines directional atherectomy capabilities with real-time intravascular visualization to remove plaque from blocked arteries. The minimally invasive catheter is designed to remove plaque, while avoiding the disruption of normal arterial wall structures.

“While today is a big day for Avinger, it’s an even bigger day for physicians and hospitals looking for better ways to treat patients suffering from vascular disease. Today we are one step closer,” said John B. Simpson, M.D., Ph.D., Avinger founder and CEO. “We designed Pantheris to help physicians better understand what is going on inside the artery as they are treating it. There isn’t a physician on the planet that doesn’t want more information about their patients’ disease state with the ability to act on it in real time.”

“For the first time ever, I am able to visualize the inside of the artery and selectively remove plaque without disrupting the healthy portion of the vessel. This has the potential to revolutionize the treatment of vascular disease,” added Pigott.

“We are convinced that Avinger’s Pantheris catheter will be a major step forward for our patients and for the entire medical community as the increased precision allowed by direct visualization is immediate and significant,” said VISION co-principal investigators William Crowder, M.D., and J. Gray Bennett, M.D., of St. Dominic Hospital, Jackson, Miss.

For more information: www.avinger.com


Related Content

News | Cardiovascular Clinical Studies

February 21, 2024 — An 80-year-old woman from Frankenmuth, Michigan is the first Henry Ford Health structural heart ...

Home February 21, 2024
Home
News | Cardiovascular Clinical Studies

February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...

Home February 15, 2024
Home
News | Cardiovascular Clinical Studies

January 3, 2024 — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce the completion of ...

Home January 03, 2024
Home
News | Cardiovascular Clinical Studies

December 19, 2023 — Peerbridge Health has announce the successful completion and findings of its prospective ...

Home December 19, 2023
Home
News | Cardiovascular Clinical Studies

December 14, 2023 — Published results of a large, national heart attack study show that patients with a life-threatening ...

Home December 14, 2023
Home
News | Cardiovascular Clinical Studies

December 11, 2023 — A world without cardiovascular disease (CVD) is possible, yet millions of lives are lost prematurely ...

Home December 11, 2023
Home
News | Cardiovascular Clinical Studies

December 8, 2023 — Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac ...

Home December 08, 2023
Home
News | Cardiovascular Clinical Studies

November 29, 2023 — Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of ...

Home November 29, 2023
Home
Subscribe Now